Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

This phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in patients with primary and secondary myelofibrosis. Donor hematopoietic stem cell transplantation (HSCT) is currently the only treatment with proven curative potential for myelofibrosis, however, myelofibrosis patients have a high risk for developing graft versus host disease post-transplant. Graft versus host disease is a condition where the transplanted cells from a donor can attack the body's normal cells. Ruxolitinib, a janus-associated kinase (JAK) inhibitor, is known to decrease inflammatory signals, which may reduce spleen size and decrease symptoms such as night sweats and weight loss. Administering ruxolitinib before, during, and after transplant may decrease the incidence and severity of graft versus host disease, increase survival, and improve quality of life in patients with primary and secondary myelofibrosis.

NCT Number	NCT04384692
Lead Sponsor	Fred Hutchinson Cancer Center
Conditions	Primary Myelofibrosis, Secondary Myelofibrosis
Enrollment	53 participants
Start Date	2020-12-18
Primary Completion	2026-04-03 (estimated)
Study Completion	2030-04-23 (estimated)
Updated on ClinicalTrials.gov	2026-04-14